Drug Development

Blog Post

Clinical Trial Alert: Phase 2 Study of Pegcetacoplan in Adults with Sporadic ALS (MERIDIAN)

By MDA Staff | March 31, 2021
Blog Post

Clinical Trial Alert: Phase 1/2 Study of AT845 in Late-Onset Pompe Disease

By MDA Staff | March 16, 2021
Blog Post

Clinical Trial Alert: Observational Study to Identify Biomarkers in Individuals Receiving Radicava for ALS

By MDA Staff | March 10, 2021
Blog Post

Clinical Trial Alert: Phase 3 Study of Zilucoplan in Individuals With Generalized Myasthenia Gravis

By MDA Staff | March 2, 2021
Blog Post

Clinical Trial Alert: Phase 3 Study of Rozanolixizumab in Individuals With Generalized Myasthenia Gravis

By MDA Staff | February 23, 2021
Blog Post

How Expedited Drug Approval Impacts the Neuromuscular Disease Treatment Landscape

By Sujatha Gurunathan | February 4, 2021
Blog Post

MDA’s 2021 Advocacy Plan

By Mark Fisher | February 2, 2021
Blog Post

Once a Wild Idea, Successful First-Generation Exon-Skipping Therapies Pave the Way for Personalized Treatments

By Sujatha Gurunathan | November 17, 2020
Blog Post

Scholar Rock Announces Positive Results from Interim Analysis of TOPAZ Phase 2 Study of SRK-015 to Treat SMA

By Sujatha Gurunathan | October 28, 2020
Blog Post

Amylyx Announces More Results from Study of AMX0035 to Treat ALS

By Sujatha Gurunathan | October 19, 2020